Anixa Biosciences Capital Expenditures (CapEx) Growth & History (ANIX)

Anixa Biosciences's capital expenditures (capex) was $15,791 for fiscal 2020.

View full Anixa Biosciences company overview

Anixa Biosciences annual capital expenditures (capex) history

Anixa Biosciences annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20202020-10-31$15,791−$159,666−91.00%
20192019-10-31$175,457$137,053+356.87%
20182018-10-31$38,404$8,216+27.22%
20172017-10-31$30,188−$116,333−79.40%
20162016-10-31$146,521$91,745+167.49%
20152015-10-31$54,776$48,092+719.51%
20142014-10-31$6,684
20122012-10-31$1,600−$7,428−82.28%
20112011-10-31$9,028$6,959+336.35%
20102010-10-31$2,069

Anixa Biosciences capital expenditures (capex) trends

Over the last five fiscal years, Anixa Biosciences's capital expenditures (capex) decreased from $54,776 to $15,791, a change of −$38,985. The latest reported quarter, Q4 2020, shows $0.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Anixa Biosciences source filings ↗

Community posts

It’s quiet here.

No posts about ANIX yet. Start the conversation.

Write the first post